Evidence map›Paper›PMID 42194873›Full record

ReviewJournal of clinical medicine2026

A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.

Linda Nici, Bartolome R Celli, David Mannino, Steve I Rennard, Alvar Agusti, Suzanne Lareau, Paula Meek, Denis O'Donnell, J Alberto Neder, Jadwiga A Wedzicha and 3 more

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linda NiciThe Warren Alpert Medical School, Brown University, 222 Richmond St., Providence, RI 02903, USA.
Bartolome R CelliDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
David ManninoCOPD Foundation, Miami, FL 33134, USA.
Steve I RennardDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Alvar AgustiRespiratory Institute, Hospital Clinic, University of Barcelona, 08007 Barcelona, Spain.
Suzanne LareauCollege of Nursing, University of Colorado, Denver Anschutz Medical Campus, ED 2 North, 13120 East 19th Ave., Aurora, CO 80045, USA.
Paula MeekCollege of Nursing, University of Utah, 10 2000 E, Salt Lake City, UT 84112, USA.ORCID 0000-0003-2648-5619
Denis O'DonnellDepartment of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
J Alberto NederDepartment of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Jadwiga A WedzichaNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Richard CasaburiDivision of Respiratory and Critical Care Physiology and Medicine, Respiratory Research Center, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0002-8851-8589
Roger GoldsteinDepartments of Respiratory Medicine and Physical Therapy, University of Toronto, West Park Healthcare Centre (UHN), Toronto, ON M6M 2J5, Canada.ORCID 0000-0002-4236-043X
Carolyn L RochesterSection of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is highly prevalent worldwide and is the third leading cause of death. While some aspects of the disease were known since the Enlightenment, Laennec's work in the 19th century began the process of our current understanding of this disease. In this narrative review, 13 clinicians and scientists with over three centuries of cumulative experience treating and studying COPD give their perspectives on the science underpinning our modern concept of this disease and its management. These include (1) the challenges of coming up with a name for what is a complex syndrome; (2) the evolution of our thinking on the natural history of the disease; (3) the importance of particulate matter inhalation in its pathogenesis; (4) the often-overlooked but important-and often treatable-systemic effects of the disease that contribute to its morbidity and mortality; (5) the changes in our perspective of not just addressing pathologic or physiologic abnormalities but also measuring outcomes, such as breathlessness or health-related quality of life, that are of considerable importance to the patient; (6) the role of pharmacologic therapy in not only providing symptomatic relief by increasing airway caliber but also in disease modification, especially by reducing exacerbation frequency; (7) lung hyperinflation as an essential feature of COPD pathophysiology, driving symptom burden, exercise limitation, and mortality risk; (8) long-term oxygen therapy, despite being demonstrated to prolong survival in a defined set of hypoxemic patients with COPD, still having unanswered questions regarding its application and delivery; and (9) pulmonary rehabilitation, a major component of the non-pharmacologic treatment of COPD patients and prominently situated in clinical guidelines for this disease. While this, by necessity, must be a brief review of a very complex disease, the perspectives of these esteemed clinicians and scientists should be of use to other clinicians in understanding and managing this disease.

Indexed as

chronic bronchitisCOPDemphysemaexacerbationshyperinflationnatural historynomenclatureoxygenpatient-reported outcomesPROpulmonary rehabilitation

Identifiers

PMID42194873
PMCPMC13208065

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.